Starling Oncology, Inc. (STLN) Operating margin 2020–2025
Starling Oncology, Inc. (STLN) operating margin by fiscal year — reported operating income divided by reported revenue.
-7.2%FY2025 · since FY2020: -4.4% → -7.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -7.2% | +8.1 pp |
| FY2024 | -15.3% | +8.5 pp |
| FY2023 | -23.8% | +8.7 pp |
| FY2022 | -32.5% | -9.9 pp |
| FY2021 | -22.6% | -18.2 pp |
| FY2020 | -4.4% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More STLN financial trends
STLN RevenueSTLN Net incomeSTLN Net marginSTLN Gross profitSTLN Gross marginSTLN Operating incomeSTLN Operating cash flowSTLN Free cash flowSTLN Capital expendituresSTLN Return on equitySTLN Stock buybacksSTLN Dividends paidSTLN Total assetsSTLN Total liabilitiesSTLN Shareholders’ equitySTLN overview →